Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05317689Phase 1Active Not Recruiting

Comparing the Effects of Psilocin and Psilocybin in Healthy Adults

Role: collaborator

NCT06666010Phase 2Not Yet Recruiting

PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study

Role: lead

NCT06608459Phase 2Not Yet Recruiting

PEX010-Assisted Therapy for Opioid Use Disorder (OUD): a Feasibility Study

Role: lead

NCT06378229Phase 2Recruiting

Psilocybin for Hospitalized Patients with Treatment-resistant Depression

Role: collaborator

All 4 trials loaded